Interleukin-8 and Interleukin-6 Are Biomarkers of Poor Prognosis in Esophageal Squamous Cell Carcinoma

Simple Summary Esophageal squamous cell carcinoma (SCC) is an extremely aggressive malignancy with high mortality rates. An important variable in understanding this aggressiveness seems to be in controlling the proliferation of malignant cells directly or indirectly related to systemic levels of inflammatory cytokines. Therefore, we sought to assess the usefulness of determining the most prominent cytokines in this context and their potential role as diagnostic biomarkers. For this purpose, we analyzed the levels of IL-1β, IL-6, IL-8, IL-10, TNF-α and IL-12p70 in a group of 70 patients with ESCC and 70 healthy individuals and detected increased levels of IL-1β, IL-6, IL-8 and IL-10 in patients with ESCC compared to controls. We also observed that patients with low IL-6, IL-8 had a significantly higher overall survival rate. To confirm these findings, we studied Kyse-30 and Kyse-410 cells cultured in mice and confirmed that increased growth of these cells was associated with recruitment/accumulation of intratumoral polymorphonuclear leukocytes. Abstract Esophageal squamous cell carcinoma (ESCC) is a common type of cancer characterized by fast progression and high mortality rates, which generally implies a poor prognosis at time of diagnosis. Intricate interaction networks of cytokines produced by resident and inflammatory cells in the tumor microenvironment play crucial roles in ESCC development and metastasis, thus influencing therapy efficiency. As such, cytokines are the most prominent targets for specific therapies and prognostic parameters to predict tumor progression and aggressiveness. In this work, we examined the association between ESCC progression and the systemic levels of inflammatory cytokines to determine their usefulness as diagnostic biomarkers. We analyzed the levels of IL-1β, IL-6, IL-8, IL-10, TNF-α e IL-12p70 in a group of 70 ESCC patients and 70 healthy individuals using Cytometric Bead Array (CBA) technology. We detected increased levels of IL-1β, IL-6, IL-8, and IL-10 in ESCC patients compared to controls. However, multivariate analysis revealed that only IL8 was an independent prognostic factor for ESCC, as were the well-known risk factors: alcohol consumption, tobacco usage, and exposure to pesticides/insecticides. Importantly, patients with low IL-6, IL-8, TNM I/II, or those who underwent surgery had a significantly higher overall survival rate. We also studied cultured Kyse-30 and Kyse-410 cells in mice. We determined that the ESCC cell line Kyse-30 grew more aggressively than the Kyse-410 cell line. This enhanced growth was associated with the recruitment/accumulation of intratumoral polymorphonuclear leukocytes. In conclusion, our data suggest IL-8 as a valuable prognostic factor with potential as a biomarker for ESCC.

[1]  S. Reznik,et al.  Update on Management of Squamous Cell Esophageal Cancer , 2022, Current Oncology Reports.

[2]  I. Musa,et al.  Esophageal cancer epidemiology, diagnosis, and management in Sudan - A review. , 2021, The Medical journal of Malaysia.

[3]  I. Soerjomataram,et al.  International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence , 2021, The American journal of gastroenterology.

[4]  Yingyong Hou,et al.  Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, JAMA surgery.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  D. Bedognetti,et al.  Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy , 2021, Molecular cancer.

[7]  J. Gibbs,et al.  Esophageal cancer: the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt. , 2020, Journal of gastrointestinal oncology.

[8]  T. Sunkara,et al.  Epidemiology of esophageal cancer: update in global trends, etiology and risk factors , 2020, Clinical Journal of Gastroenterology.

[9]  Alan D. Lopez,et al.  The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.

[10]  Mingyao Liu,et al.  Chemokines and their receptors as biomarkers in esophageal cancer , 2019, Esophagus.

[11]  J. Schlom,et al.  Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors , 2019, Journal of Immunotherapy for Cancer.

[12]  P. Muszyński,et al.  Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients , 2019, Clinical and Experimental Medicine.

[13]  R. Grover,et al.  Clinical significance of interleukin-6 in diagnosis of lung, oral, esophageal, and gall bladder carcinomas , 2018, Journal of cancer research and therapeutics.

[14]  Q. Tong,et al.  Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips , 2018, OncoTargets and therapy.

[15]  Jang-Ming Lee,et al.  Circulating Interleukin-6 is Associated with Prognosis and Genetic Polymorphisms of MIR608 in Patients with Esophageal Squamous Cell Carcinoma , 2018, Annals of Surgical Oncology.

[16]  M. Shaul,et al.  Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function , 2018, The FEBS journal.

[17]  M. Yashiro,et al.  Neutrophils in primary gastric tumors are correlated with neutrophil infiltration in tumor-draining lymph nodes and the systemic inflammatory response , 2018, BMC Immunology.

[18]  K. Schalper,et al.  Interleukin-8 in cancer pathogenesis, treatment and follow-up. , 2017, Cancer treatment reviews.

[19]  J. Fregnani,et al.  HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors? , 2017, Infectious Agents and Cancer.

[20]  A. Longatto-Filho,et al.  High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer , 2017, PloS one.

[21]  A. Longatto-Filho,et al.  The Relation of HPV Infection and Expression of p53 and p16 Proteins in Esophageal Squamous Cells Carcinoma , 2017, Journal of Cancer.

[22]  Sheng-Jie Yu,et al.  Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.

[23]  A. Wikman,et al.  Toward improved survivorship: supportive care needs of esophageal cancer patients, a literature review. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[24]  D. Forman,et al.  The burden of oesophageal cancer in Central and South America. , 2016, Cancer epidemiology.

[25]  Dan Xie,et al.  Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2 , 2016, Clinical Cancer Research.

[26]  Adam J. Bass,et al.  The Tumor Microenvironment in Esophageal Cancer , 2016, Oncogene.

[27]  W. Mao,et al.  Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review , 2015, Journal of Cancer.

[28]  Jun Zhang,et al.  Diagnostic Value of Multiple Tumor Markers for Patients with Esophageal Carcinoma , 2015, PloS one.

[29]  T. Omori,et al.  Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. , 2013, Surgery.

[30]  D. Ichikawa,et al.  Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. , 2013, Anticancer research.

[31]  K. Dvorak,et al.  Role of interleukin-6 in Barrett's esophagus pathogenesis. , 2013, World journal of gastroenterology.

[32]  B. Mroczko,et al.  Interleukin 6 and C-reactive protein in esophageal cancer. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[33]  S. Albelda,et al.  Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.

[34]  G. Sethi,et al.  Multifaceted link between cancer and inflammation. , 2012, Bioscience reports.

[35]  A. Richmond,et al.  Chemokines and chemokine receptors: new insights into cancer-related inflammation. , 2010, Trends in molecular medicine.

[36]  E. D. de Vries,et al.  Role of chemokines and their receptors in cancer. , 2009, Current pharmaceutical design.

[37]  M. Krzystek-Korpacka,et al.  Elevation of circulating interleukin-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas--implication for clinical evaluation of cancer patient. , 2008, Cytokine.

[38]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[39]  M. Gazouli,et al.  Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. , 2005, World journal of gastroenterology.

[40]  Megumi Baba,et al.  The role of circulating IL‐8 and VEGF protein in the progression of gastric cancer , 2003, Cancer science.

[41]  Attila Tárnok,et al.  Cytometric bead array to measure six cytokines in twenty-five microliters of serum. , 2003, Clinical chemistry.

[42]  W. Wood,et al.  Chemokine binding and activities mediated by the mouse IL-8 receptor. , 1995, Journal of immunology.

[43]  L. F. Kolakowski,et al.  The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. , 1994, The Journal of biological chemistry.

[44]  E. Appella,et al.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.

[45]  E. Appella,et al.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Forman,et al.  Etiology of oesophageal cancer ( C 15 ) in Central and South America , 2016 .

[47]  Kaijuan Wang,et al.  Serum autoantibodies in the early detection of esophageal cancer: a systematic review , 2014, Tumor Biology.

[48]  E. McArthur,et al.  Esophageal carcinoma. , 2014, The New England journal of medicine.

[49]  J. Luketich,et al.  Oesophageal carcinoma , 2013, The Lancet.

[50]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.